Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America
September 26, 2022 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree to Present at the Ladenburg Thalmann Healthcare Conference
September 21, 2022 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
August 23, 2022 08:00 ET
|
Windtree Therapeutics
Windtree may receive up to $78.9 million in development, regulatory and commercial milestones plus low double digit royaltiesDevelopment and all other costs to be assumed by Lee’s Pharmaceutical and...
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
August 11, 2022 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value
June 29, 2022 08:00 ET
|
Windtree Therapeutics
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM:...
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid
May 23, 2022 10:12 ET
|
Windtree Therapeutics
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also...
Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock
May 16, 2022 07:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
May 05, 2022 16:05 ET
|
Windtree Therapeutics
Announced positive topline results from Phase 2 SEISMiC study of istaroxime in early cardiogenic shock Late-breaker presentation of additional SEISMiC study results at the European Society of...
Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference
April 20, 2022 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...